ライフサイエンスコーパス: interleukin-13

1 nterleukin 4, interleukin 5, interleukin 10, interleukin 13).

2 of CD4+ T cells producing interleukin-4 and interleukin-13.

3 canonical T(H)2 cytokines interleukin-4 and interleukin-13.

4 lic esophagitis, including interleukin-5 and interleukin-13.

5 tly reduced Th2 cytokines, interleukin-4 and interleukin-13.

6 h-2-type cytokines such as interleukin-4 and interleukin-13.

7 nes, in the first instance interleukin-4 and interleukin-13.

8 beta1, connective tissue growth factor, and interleukin-13.

9 0, 95% CI 0.30-0.81, interaction p=0.02) and interleukin-13 (0.52, 0.34-0.82, 0.0005) response to tet

10 o had a pretreatment profile consistent with interleukin-13 activity.

11 ansforming growth factor beta1 (TGFbeta1) or interleukin-13, although active TGFbeta1 was present loc

12 ome 11, in a region containing the genes for interleukin 13 and granulocyte/macrophage-colony-stimula

13 9 cell lines in response to stimulation with interleukin 13 and lipopolysaccharide.

14 d the levels of predicted targets, including interleukin-13 and 3 tumor necrosis factor receptors (TN

15 f a recombinant chimeric protein composed of interleukin-13 and a mutated form of Pseudomonas exotoxi

16 id cells (ILCs), resulting in suppression of interleukin-13 and hallmark features of the allergic res

17 ined elevated levels of interferon-gamma and interleukin-13 and increased levels of CCR1 ligands CCL3

18 olony-stimulating factor), and interleukins (interleukin-13 and interleukin-16).

19 Interleukin-13 and interleukin-4 were unable to block in

20 ment is under immune control by the cytokine interleukin-13 and the chemokine CXCL10.

21 elopment of inflammatory Th2 cells producing interleukin-13 and tumor necrosis factor in vitro.

22 ids in HMC-1 cells resulted in activation of interleukin-13 and tumor necrosis factor-alpha promoters

23 in the concentration of interferon gamma and interleukin 13, and in the amount of proliferation betwe

24 of HIV infection, including interleukin 10, interleukin 13, and interleukin 22.

25 ate regulator of three genes, interleukin-4, interleukin-13, and interleukin-5, spread over 120 kilob

26 yte-macrophage colony-stimulating factor and interleukin-13, and natural killer cell enhancing factor

27 phageal eosinophilia and that interleukin-4, interleukin-13, and STAT6 contributed to a lesser extent

28 In contrast, with the exception of interleukin-13, anti-inflammatory cytokine production wa

29 Interleukin-4 and Interleukin-13 are cytokines critical to the development

30 However, it blocked interleukin-13 as evidenced by the effect on interleukin

31 Leishmania donovani-infected interleukin-13-/- BALB/c mice showed impaired initial ga

32 We have found that the primary interleukin-13-binding protein IL-13Ralpha2 chain plays

33 tured mast cells secreted greater amounts of interleukin-13 but much less MIP-1beta and interleukin-6

34 cently, we have shown that interleukin-4 and interleukin-13 can independently induce human macrophage

35 cells and that these cytokines, particularly interleukin-13, can act directly on airway smooth muscle

36 also led to a decrease in interleukin-4 and interleukin-13 concentrations, which drive the Th2 respo

37 childhood TBM based on CSF concentrations of interleukin 13 (cutoff value, 37.26 pg/mL), vascular end

38 LPS exposure, and increasing PI3K activity (interleukin-13) decreased release of prostaglandin E2 af

39 Interleukin 13-deficient (IL-13-/-) mice express a defec

40 Thus, it may be possible to promote interleukin-13-dependent hepatobiliary expansion without

41 By itself, interleukin-13 does not appear to materially influence a

42 t internalization of Candida albicans during interleukin-13-enhanced, MR-mediated phagocytosis.

43 ytes and mediators, including interleukin-5, interleukin-13, eotaxin, prostanoids and cysteinyl leuko

44 to treatment is heterogeneity in the role of interleukin-13 expression in the clinical asthma phenoty

45 ntly been reported for the interleukin-4 and interleukin-13 genes (IL4 and IL13) with the interleukin

46 Interleukin-13 has been implicated as a key factor in as

47 lonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asth

48 or 24 of 27 analytes, with interleukin-8 and interleukin-13 higher in AML and vascular endothelial gr

49 uman natural killer (NK) cells revealed that interleukin 13 (IL-13) and interferon gamma (IFN-gamma)

50 Interleukin 13 (IL-13) is a key factor in fibrotic disea

51 The cytokine interleukin 13 (IL-13) is a major effector molecule for

52 ILC2-derived interleukin 13 (IL-13) is critical for eliciting product

53 Associations between interleukin 13 (IL-13) levels and aGVHD were by far the

54 to the lung, bred these mice with CC10-rtTA-interleukin 13 (IL-13) mice in which IL-13 was overexpre

55 ad elevated serum levels of the Th2 cytokine interleukin 13 (IL-13) on day 6 after T-cell transfer co

56 tain their function and selectively maintain interleukin 13 (IL-13) production via increased acquisit

57 cells in situ exhibit on their surfaces the interleukin 13 (IL-13) receptor designated IL13Ralpha2.

58 The level of the anti-inflammatory cytokine interleukin 13 (IL-13) was lower in the serum and lungs

59 Type 2 helper T cells (TH2 cells) produce interleukin 13 (IL-13) when stimulated by papain or hous

60 fact, liver fibrosis, which is dependent on interleukin 13 (IL-13), increased by a factor of more th

61 (IL-4)(-/-) BALB/c mice have indicated that interleukin 13 (IL-13), whose receptor shares the IL-4Ra

62 ting an activated phenotype and induction of interleukin 13 (IL-13)- and GATA3-expressing Th2-type CD

63 ix metalloproteinase 2 (MMP2), as part of an interleukin 13 (IL-13)-dependent regulatory loop, dampen

64 previously unknown pathway that required the interleukin 13 (IL-13)-IL-33 axis and cells of the non-T

65 In addition, this allergic response required interleukin-13 (IL-13) (the response was absent in IL-13

66 chanism dependent on interleukin-4 (IL-4) or interleukin-13 (IL-13) activation of signal transducer a

67 Interleukin-13 (IL-13) activation of the STAT6 signaling

68 (CB) is a recombinant protein consisting of interleukin-13 (IL-13) and a truncated form of Pseudomon

69 reater airway necrosis, and higher levels of interleukin-13 (IL-13) and airway mucin expression than

70 Interleukin-13 (IL-13) and IL-4 are cytokines produced b

71 Interleukin-13 (IL-13) and IL-4 concentrations were meas

72 Here we show that interleukin-13 (IL-13) and its receptors IL-13Ralpha1 an

73 re of allergic lung disease, is regulated by interleukin-13 (IL-13) as well as the eotaxin chemokines

74 Interleukin-13 (IL-13) belongs to the IL-4 gene family.

75 te, suppression depended on the secretion of interleukin-13 (IL-13) by iNKT cells because an antibody

76 roup 2 innate lymphoid cells (ILC2s) release interleukin-13 (IL-13) during protective immunity to hel

77 have clearly demonstrated that the cytokine interleukin-13 (IL-13) effectively targets glioblastoma

78 Interleukin-13 (IL-13) has been linked to the pathogenes

79 Interleukin-13 (IL-13) has emerged as a major cytokine m

80 CNTO607 is a neutralizing anti-interleukin-13 (IL-13) human monoclonal antibody obtaine

81 Despite the importance of interleukin-13 (IL-13) in systemic sclerosis (SSc) and o

82 We created a novel mutated form of human interleukin-13 (IL-13) in which a positively charged arg

83 We reported previously that interleukin-13 (IL-13) induces tyrosine phosphorylation/

84 Interleukin-13 (IL-13) is a critical mediator of pulmona

85 Interleukin-13 (IL-13) is a cytokine secreted by Th2 lym

86 Interleukin-13 (IL-13) is a cytokine that has been shown

87 Interleukin-13 (IL-13) is a mediator of pulmonary mucus

88 Interleukin-13 (IL-13) is a pleiotropic cytokine that ca

89 Interleukin-13 (IL-13) is the dominant effector cytokine

90 nt protein-1 (MCP-1) and a later increase in interleukin-13 (IL-13) levels in the peritoneal cavity.

91 ates induced variable disease severity, lung interleukin-13 (IL-13) levels, and gob-5 levels in BALB/

92 h1) and Th2 cytokine mRNAs, we observed that interleukin-13 (IL-13) mRNA was highly expressed in HTLV

93 Deficient interleukin-13 (IL-13) production by NT cells and reduce

94 We have previously shown that aberrant interleukin-13 (IL-13) production by peripheral blood ef

95 Interleukin-13 (IL-13) receptor alpha2 (IL-13Ralpha2), a

96 Ls also had high levels of expression of the interleukin-13 (IL-13) receptor and downstream effectors

97 sed the signaling chain of the high affinity interleukin-13 (IL-13) receptor IL-13Ralpha1.

98 Exposure of the epithelium to interleukin-13 (IL-13) reconstituted the goblet cell hyp

99 T6 in KSHV-associated PEL cells results from interleukin-13 (IL-13) secretion and reduced expression

100 hat STAT6 activation tightly correlates with interleukin-13 (IL-13) secretion, JAK1/2 tyrosine phosph

101 from wild-type BALB/c mice are polarized by interleukin-13 (IL-13) towards a tumor-promoting M2 phen

102 Likewise, CD4+ expression of interleukin-13 (IL-13) was increased (poor responders: 4

103 gh levels of the profibrotic type 2 cytokine interleukin-13 (IL-13) were produced following activatio

104 Interleukin-13 (IL-13), a multifunctional cytokine, has

105 Interleukin-13 (IL-13), a predominantly Th2-derived cyto

106 Interleukin-13 (IL-13), a T-helper 2 cytokine, is a key

107 Interleukin-13 (IL-13), a Th2 cytokine, plays a pivotal

108 ansforming growth factor-beta (TGF-beta) and interleukin-13 (IL-13), cytokines implicated in remodeli

109 ion and is associated with the production of interleukin-13 (IL-13), in resistance to this nematode.

110 Therefore, we tested the hypothesis that interleukin-13 (IL-13), which influences the differentia

111 is induced via a T helper-2 (Th2)-specific, interleukin-13 (IL-13)-mediated pathway in epithelial ce

112 adoxically resulted in dramatic expansion of interleukin-13 (IL-13)-producing ILC2s and resistance to

113 etermined high-resolution structure of human interleukin-13 (IL-13).

114 of receptors for immune regulatory cytokine, interleukin-13 (IL-13).

115 iated cultured bronchial epithelial cells to interleukin-13 (IL-13).

116 n type 2 T cells, we demonstrate that type 2 interleukin-13+ (IL-13+) T cells (CD4+ or CD8+) in human

117 those encoding human interleukin 4 (IL4) and interleukin 13 (IL13 ), which induce IgE class switching

118 Interleukin 13 (IL13) belongs to a family of cytokines w

119 Interleukin 13 (IL13) is a T-helper type 2 (Th2) cytokin

120 ), interleukin 4 (Il4), interleukin 5 (Il5), interleukin 13 (Il13), and granulocyte-macrophage colony

121 cancers (gliomas) express a receptor (R) for interleukin 13 (IL13).

122 es express large number of receptors (R) for interleukin 13 (IL13).

123 tail, 2 (KIR3DL2); interleukin 4 (IL4); and interleukin 13 (IL13).

124 Expression of the cytokine interleukin-13 (IL13) is critical for Th2 immune respons

125 Binding of interleukin-13 (IL13) or interleukin-4 (IL4) to the IL4

126 nted that alpha-helices A, C, and D in human interleukin-13 (IL13) participate in interaction with it

127 dating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis.

128 o too have monoclonal antibodies targeted to interleukin 13 in patients with a type 2 allergic phenot

129 The level of interleukin-13 in bronchoalveolar lavage fluid from MCMV

130 have revealed direct and distinct roles for interleukin-13 in fibrosis, steatosis, cholestasis, and

131 ecreased allergen-induced AHR, production of interleukin-13 in lung tissue, and lung eosinophilia.

132 a, goblet cell metaplasia, and expression of interleukin-13 in response to low-dose aerosolized aller

133 e-1 response, and enhanced interleukin-5 and interleukin-13 in the type-2 response.

134 dy of lebrikizumab, a monoclonal antibody to interleukin-13, in 219 adults who had asthma that was in

135 ell immunity that involves interleukin-5 and interleukin-13-induced esophageal epithelial cell respon

136 Interleukin-4 or interleukin-13 induction of monocyte-macrophage fusion p

137 d not, whereas antibodies to interleukin 10, interleukin 13, interferon alpha, or interferon gamma mo

138 evated production of interleukin 10 (IL-10), interleukin 13, interferon gamma, CXCL9, and CCL2 compar

139 leukin-10, interleukin-12/interleukin-23p40, interleukin-13, interleukin-17, interleukin-18, interfer

140 ory cytokines (interleukin-3, interleukin-6, interleukin-13, interleukin-17, macrophage inflammatory

141 interleukin-4, interleukin-5, interleukin-7, interleukin-13, interleukin-17, macrophage inflammatory

142 Interleukin 13 is a central mediator of asthma.

143 cells from the actions of interleukin 4 and interleukin 13, is used as treatment for severe allergic

144 ortisol, AXL receptor kinase, interleukin-3, interleukin-13, matrix metalloproteinase-9 total, apolip

145 was observed to block the interleukin-4- or interleukin-13-mediated induction of CDw60 on cultured k

146 leukin-5, anti-interleukin-4Ralpha, and anti-interleukin-13 monoclonal antibodies in patients with se

147 In phase 2 trials, lebrikizumab, an anti-interleukin-13 monoclonal antibody, reduced exacerbation

148 Tralokinumab is a human interleukin-13 neutralising monoclonal antibody.

149 d antibodies against IgE, interleukin 5, and interleukin 13, offer hope to improve the quality of lif

150 effect of the cytokines interferon-gamma and interleukin-13 or interleukin-4 on keratinocytes, alone

151 h those identified by microarray analysis of interleukin-13-overexpressing and integrin-beta6-deficie

152 ogressive models of liver disease induced by interleukin-13 overexpression or after infection with Sc

153 ng early ART had higher day-14 CSF levels of interleukin-13 (P = .04), sCD14 (P = .04), sCD163 (P = .

154 ncreased secretion of eotaxin in response to interleukin-13 (P = 0.04).

155 lity of DPP-4 and periostin as biomarkers of interleukin-13 pathway activation.

156 Biological agents directed against the interleukin-13 pathway and new immunoregulatory agents t

157 oplatform, when subsequently conjugated with interleukin-13 peptide IL-13-Gd3N@C80(OH)x(NH2)y, exhibi

158 te that this agent can be conjugated with an interleukin-13 peptide that is designed to target an ove

159 macrophages stimulated with interleukin 4 + interleukin 13 produce arginase I, which decreases the e

160 ive immune response and is driven instead by interleukin-13 produced by macrophages that have been st

161 tly induces tuft cell expansion by promoting interleukin-13 production by innate lymphoid cells.

162 SLP or OX40L inhibit breast tumor growth and interleukin-13 production in a xenograft model.

163 ore robust interleukin-4, interleukin-5, and interleukin-13 production than their mature naive counte

164 D4(+) and CD8(+) T cells are associated with interleukin-13 production.

165 have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).

166 ubsets, but Th1 cells express high levels of interleukin 13 receptor alpha1 (IL-13R alpha 1), which h

167 Interleukin 13 receptor alpha2 (IL-13R(alpha)2) chain is

168 olymorphonucleocyte (PMN) infiltration in an interleukin 13 receptor alpha2 (IL-13Ralpha2)-dependent

169 s, CCN proteins, fibroblast growth factor 2, interleukin 13 receptor components, proteases, antiprote

170 The interleukin-13 receptor (IL-13R) complex is composed of

171 ant glioma cell lines express high levels of interleukin-13 receptor (IL-13R).

172 GAAs were EphA2, interleukin-13 receptor alpha 2 (IL-13Ralpha2), and surv

173 cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Ralpha2).

174 class II, beta(2)-microglobulin, clusterin, interleukin-13 receptor alpha chain, ovotransferrin, a s

175 Interleukin-13 receptor alpha-1 chain (IL-13Ralpha1) bin

176 Restricted and high-level expression of interleukin-13 receptor alpha2 (IL-13Ralpha2) in a major

177 The interleukin-13 receptor alpha2 (IL-13Ralpha2) is a cance

178 The high affinity interleukin-13 receptor alpha2 (IL13Ralpha2) is selectiv

179 Whereas interleukin-13 receptor alpha2 chain (IL-13Ralpha2) is o

180 lines have been reported to overexpress the interleukin-13 receptor alpha2 subunit (IL13Ralpha2) rel

181 Although interleukin-13 receptors (IL-13R) are overexpressed on s

182 rcinoma (RCC) cells express large numbers of interleukin-13 receptors (IL-13R), a newly described hem

183 interleukin-13 as evidenced by the effect on interleukin-13-related pharmacodynamic biomarkers, and c

184 GATA3-positive cells and the level of interleukin 13 secretion in response to P. falciparum-in

185 nd STAT6 signaling are critical mediators of interleukin 13 signaling in CMs.

186 Using transgenic mice with interleukin-13 signaling genetically disrupted in hepato

187 ously controlled but distinctly regulated by interleukin-13 signaling.

188 oclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediate

189 h2) response, or the pathogenic Th2 cytokine interleukin 13 significantly ameliorated pulmonary arter

190 have shown that the type 2 effector cytokine interleukin-13 simultaneously, yet independently, direct

191 eline (2.5-fold higher; p = 0.004) and after interleukin-13 stimulation (13-fold higher; p = 0.0001).

192 We hypothesized that anti-interleukin-13 therapy would benefit patients with asthm

193 een in atopic asthma, with interleukin 4 and interleukin 13 thought to have a role in the physiologic

194 inhibiting the binding of interleukin 4 and interleukin 13 to interleukin-4Ralpha receptor complexes

195 terleukin-9, interleukin-10, interleukin-12, interleukin-13, tumor necrosis factor-alpha, interferon-

196 body) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numer

197 ts secrete high levels of interleukin 10 and interleukin 13 upon in vitro restimulation, which are al

198 duction of CDw60 involving interleukin-4, or interleukin-13 was antagonized by interferon-gamma.

199 kin 1beta, interleukin 2, interleukin 6, and interleukin 13 were significantly greater in NW specimen

200 raction and MMP secretion in the presence of interleukin-13 were also observed.

201 am regulators of the core network, including interleukin 13, which induced CM cell cycle entry and ST

202 complexes of the cytokines interleukin-4 and interleukin-13 with their receptors, showing how events